Drug name - Revlimid
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7855217 | CELGENE | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(2 years from now) | |
| US7465800 | CELGENE | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056120 | CELGENE | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(7 months from now) | |
| US7189740 | CELGENE | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(7 months from now) | |
| US8404717 | CELGENE | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(7 months from now) | |
| US8530498 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(8 months from now) | |
| US9155730 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(8 months from now) | |
| US8648095 | CELGENE | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(8 months from now) | |
| US9101621 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(8 months from now) | |
| US9101622 | CELGENE | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(8 months from now) | |
| US9393238 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(8 months from now) | |
| US8492406 | CELGENE | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(1 year, 1 month from now) | |
| US7968569 | CELGENE | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(1 year, 1 month from now) | |
| US7468363 | CELGENE | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(1 year, 1 month from now) | |
| US8741929 | CELGENE | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(5 years from now) | |
Drugs and Companies using LENALIDOMIDE ingredient
Treatment: Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone; Use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct); Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma; Use of revlimid (lenalidomide) for the treatment of previously treated marginal zone lymphoma in combination with a rituximab product; use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib; use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | CAPSULE;ORAL | Prescription |
| 5MG | CAPSULE;ORAL | Prescription |
| 10MG | CAPSULE;ORAL | Prescription |
| 15MG | CAPSULE;ORAL | Prescription |
| 20MG | CAPSULE;ORAL | Prescription |
| 25MG | CAPSULE;ORAL | Prescription |